The Company is pleased to announce that its cash reserves have been further strengthened by the receipt of $1.7 million in research and development tax incentive for the 2021-22 financial year.
As commercialisation proceeds for PromarkerD, the world-leading predictive test for diabetic kidney disease, Proteomics International continues to invest in its biomarker discovery program centred on the Promarker™ technology platform and developing new fee-for-service analytical methods.
